Moderna Shares Up After Product Sales Outlook

   By Michael Dabaie 
 

Moderna Inc. shares were up 6.7% at $228.27 after the company said it signed advanced purchase agreements for product sales of about $18.5 billion.

Moderna says it has signed the agreements for 2022 for about $18.5 billion, up from the $17 billion it had unveiled in November. The company added that it signed about $3.5 billion in options, including for any potential updated Covid-19 vaccine booster candidates.

Moderna said it is in active talks for additional 2022 Covid-19 vaccine contracts.

The company said 807 millon doses of its Covid vaccine shipped globally in 2021, with about 25% going to low- and middle-income countries.

Product sales for 2021 were about $17.5 billion.

"While our Covid-19 vaccine is our first medicine to market, we have made significant progress across our pipeline of 40 development programs and now have 23 mRNA programs in clinical trials," Chief Executive Stephane Bancel said in a company release.

The company said in a presentation at the J.P. Morgan Healthcare Conference that its product strategy going into 2022 is to bring to market a pan-respiratory annual booster vaccine, which it will continuously customize.

Write to Michael Dabaie at [e-mail]

(END) Dow Jones Newswires

January 10, 2022 11:46 ET (16:46 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.